Login to Your Account



No 'negative' for Minerva as FDA agrees to single phase III schizophrenia trial

By Marie Powers
News Editor

Monday, May 15, 2017

In the second half of the year, Minerva Neurosciences Inc. plans to initiate a single phase III trial of lead candidate MIN-101 that will enroll about 500 individuals with schizophrenia to evaluate improvement in negative symptoms.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription